The Imatinib Case: A Billion-Real Reimbursement and Lessons for Reforming PDPs

This page is a translation of the original Portuguese text, provided for convenience. It deals with Brazilian law. If there is any discrepancy, the Portuguese version prevails. Read the original in Portuguese

A recent decision by the Tribunal de Contas da União (TCU, Brazil’s Federal Court of Audit) ordered a multibillion-real reimbursement to the public treasury for overpricing in the purchase of the drug imatinib through a Productive Development Partnership (Parceria para o Desenvolvimento Produtivo, or PDP). The ruling exposes structural weaknesses in the PDP model and opens the way for its revision.

The Imatinib Case and the Finding of Harm to the Public Treasury

Imatinib, an essential drug for treating chronic myeloid leukemia and other types of cancer, was the subject of a Productive Development Partnership entered into by the Ministry of Health with public and private laboratories. Under the model, the private partner transferred technology in exchange for preferential purchases by the government, with an exemption from public bidding under Article 24, item XXXII, of Law 8.666/93, a rule now carried over into Law 14.133/2021.

The technical investigation found that the price paid for the drug under the partnership far exceeded the price charged on the international market for the same active ingredient, whose patent had already expired. Projected over years of supply, the overpricing reached billions of reais. That amounts to a significant loss to the public treasury and direct harm to the Sistema Único de Saúde (SUS, Brazil’s public health system), which paid a high price for a generic drug that was widely available.

Acting under its oversight authority in Article 71 of the Constitution, the TCU ordered those responsible to make reimbursement, assigning individual conduct among public managers, private partners, and public laboratories. The decision reinforced the understanding that administrative discretion in setting reference prices in PDPs is limited by the principle of cost-effectiveness (economicidade).

The Popular Action as a Tool for Oversight and Reform

Alongside the work of the external audit body, the case highlighted the potential of the Ação Popular (Popular Action), provided for in Article 5, item LXXIII, of the Constitution and governed by Law 4.717/65, as a way for citizens to scrutinize complex public policies. The citizen-plaintiff does not merely ask the court to annul the harmful act and order reimbursement. He or she also prompts the Judiciary to take a fresh look at the institutional design that made the harm possible.

When the court dispute goes beyond the single act and reaches the underlying regulatory framework, the Popular Action becomes a catalyst for structural reform. It leads to the review of ministerial ordinances, normative instructions, and decision-making procedures that perpetuate systemic flaws, giving judicial oversight of the government a truly instructive role.

Recognizing the harm in the imatinib case does not solve the problem. Dozens of partnerships with similar clauses remain in place, along with opaque pricing methodologies and no periodic review despite falling costs in the global pharmaceutical market. In this context, the Popular Action serves a purpose that goes beyond financial redress and reaches the engineering of the public policy itself.

The citizen-plaintiff does not merely ask the court to annul the harmful act and order reimbursement. He or she also prompts the Judiciary to take a fresh look at the institutional design that made the harm possible.

Lessons for Reforming the PDP Regulatory Framework

The experience shows that the rules governing Productive Development Partnerships need to be revised. They are currently set by a series of ministerial ordinances and by Law 14.133/2021. Reference prices should use dynamic bands tied to international benchmarks, with mandatory review whenever the market level changes significantly.

Another critical point is proactive transparency about technology transfer clauses, localization timetables, and verifiable targets. Without objective milestones, the partnership becomes a perpetual purchasing arrangement, lacking the technological counterpart that justified the bidding exemption in the first place. The logic has been turned on its head, and legislation must fix it.

Finally, holding managers and partners individually accountable, as the TCU did, signals a break with a culture of administrative impunity. Combined with the work of the Public Prosecutor’s Office and with citizen action through the Popular Action, it forms an oversight structure capable of reshaping the design of future partnerships and restoring the constitutional meaning of cost-effectiveness.

Frequently Asked Questions

What are Productive Development Partnerships in the health sector?

PDPs are arrangements among the Ministry of Health, public laboratories, and private companies to bring the production of strategic drugs and inputs into Brazil. In exchange for transferring technology, the private partner receives preferential purchases from the government, without public bidding, for a fixed period.

How can the Federal Court of Audit order reimbursement to the public treasury in cases like imatinib?

The authority comes from Article 71 of the Constitution, which allows the Court of Audit to review accounts and hold responsible parties liable for harm to the public treasury. Once overpricing is identified, the court sets the amount owed, assigns individual conduct among managers and partners, and orders reimbursement. The decision has the force of an out-of-court enforceable instrument.

What role does the Popular Action play in reviewing structural public policies?

Beyond annulling harmful acts and restoring funds to the public treasury, the Popular Action can lead the Judiciary to examine the regulatory framework that allowed the harm. When well argued, it prompts reforms in ordinances, instructions, and decision-making procedures. In this way, it works as a tool for citizen oversight of complex policies and for institutional improvement.

As informações deste artigo são de caráter informativo e não substituem consulta jurídica individualizada. Cada caso possui particularidades que exigem análise específica.